ImmuPharma Hires Drug Product, Contract Development, Manufacturing Partner for Diabetes Program

05:14 AM EDT, 07/22/2026 (MT Newswires) -- ImmuPharma (IMM.L) engaged US-based Thermo Fisher Scientific as its drug product and contract development and manufacturing organisation for its Kapiglucagon program, according to a Wednesday filing. The British specialist drug discovery company expects the partner to support pharmaceutical development and preparation towards an investigational new drug submission for the program's glucagon prodrug for Type 1 diabetes applications.